Your Article Summary
AVI BioPharma Joining Russell 3000 Index
AVI BioPharma, 06/29/09
AVI BioPharma, Inc. , a developer of RNA-based drugs, announced that immediately following the close of the U.S. markets it will join the broad-market Russell 3000 Index following Russell Investments' annual reconstitution of its comprehensive set of U.S. and global equity indexes.
Today in Marketing/Media/ROI...keeping you current
Receive free subspecialty "5-minute updates" via email
Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/09/09
Nabi Biopharmaceuticals Completes Sale of PentaStaph to GlaxoSmithKline PLC
Nabi Biopharmaceuticals, 11/05/09
Shire Reports Tolerability and Clinical Effects Results of DAYTRANA from Study in Adolescents with ADHD
Shire, 11/02/09
Article Search
Sponsor


See Latest Articles


